| Literature DB >> 31435225 |
Jyotirmaya Sahoo1, Sudhir K Paidesetty2.
Abstract
OBJECTIVES: To synthesize new transitional metal complexes derived from 3-aryl-azo-4-hydroxy coumarin analogues and to evaluate their antimicrobial activities.Entities:
Keywords: Antimicrobial activity; Cobalt complexes; Coumarin analogues; Transitional metal complexes
Year: 2016 PMID: 31435225 PMCID: PMC6694993 DOI: 10.1016/j.jtumed.2016.10.004
Source DB: PubMed Journal: J Taibah Univ Med Sci ISSN: 1658-3612
Scheme 1Synthesis of coumarin based transitional metal complexes.
Physical characteristic data of the synthesized 4-hydroxy coumarin analogues and their complexes.
| Comps. | Substitution | M. formula | Rf | M. P. (°C) | Colour | Yield (%) | UV | Elemental Analysis Cal. (Found) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C | H | N | ||||||||||
| 4-Chlorophenyl HL1 | C15H9ClN2O3 | 300.03 | 301.2 | 0.7 | 235–40 | Off yellow | 91 | 409 | 59.91 (59.93) | 3.02 (3.04) | 9.32 (9.36) | |
| 4-Methoxyphenyl Hl2 | C16H12N2O4 | 296.08 | 297.0 | 0.8 | 205–10 | Brick red | 93 | 413 | 64.86 (64.91) | 4.08 (4.11) | 9.46 (9.43) | |
Figure 1FT/IR spectra of 3-((4-chlorophenyl) diazenyl)-4-hydroxy-2H-chromen-2-one (3a).
Figure 21H NMR spectra of 4-hydroxy-3-((4-methoxyphenyl)diazenyl)-2H-chromen-2-one (3b).
Figure 4LCMS of (E)-3-((4-chlorophenyl)diazenyl)-4-hydroxy-2H-chromen-2-one (HL1): (3a).
Figure 3Solvent effect of the complexes of 3a its metal complexes (plate a) and 3b its metal complexes (plate b) using DMSO.
Figure 5XRD of 4e and 4f respectively in plate a & b.
Antimicrobial activity (Zone of inhibition in mm) of the newly synthesized 4-hydroxy coumarin analogues and their complexes against different microbial strains (Mean ± S.D.) at a concentration of 1 μg μL−1.
| Comps. | |||||
|---|---|---|---|---|---|
| 17.33 ± 1.63* | 16.67 ± 2.42 | 15.33 ± 2.34 | 20.67 ± 1.86 | 25.17 ± 1.84 | |
| 19.17 ± 2.56* | 18.5 ± 3.27 | 18.83 ± 1.47* | 21.83 ± 1.84 | 26.83 ± 2.64* | |
| 19.17 ± 2.4* | 19 ± 1.1* | 18.33 ± 2.34* | 23.67 ± 2.16* | 27.5 ± 1.64* | |
| 19.17 ± 1.72* | 18 ± 1.1 | 18.83 ± 3.25* | 20.83 ± 2.56 | 14 ± 0.89 | |
| – | 14.17 ± 2.71 | 17.5 ± 1.64* | 18.33 ± 1.63 | 26.67 ± 1.03* | |
| – | 11.5 ± 0.84 | 12.67 ± 1.51 | 12.5 ± 2.35 | 11.5 ± 1.64 | |
| 21.17 ± 2.71* | 21.17 ± 4.45* | 23 ± 2.28* | 25.5 ± 2.07* | 28.17 ± 1.72* | |
| 23.17 ± 2.23* | 19.83 ± 4.07* | 21.5 ± 1.76* | 22.33 ± 3.27 | 15.83 ± 1.84 | |
| – | 14.83 ± 2.14 | 16.83 ± 2.71* | 25.17 ± 1.6* | 27 ± 2.1* | |
| – | 12.33 ± 1.51 | 12.67 ± 2.25 | 13 ± 3.1 | 10.83 ± 1.33 | |
| 12.67 ± 1.51 | 15.33 ± 1.97 | 13 ± 1.67 | 19.33 ± 4.68 | 24.17 ± 1.94 |
Results are expressed as the Mean ± S.D. (n = 6). The data were analysed by one-way ANOVA followed by Dunnett's Post Hoc test. (Statistical significance at *p < 0.05 in comparison to RA (Reference Antibiotic): ampicillin (antibacterial); fluconazole (antifungal)); –, No zone of inhibition; a, Escherichia coli; b, Klebsiella pneumonia; c, Staphylococcus aureus; d, Candida albicans; e, Cryptococcus neoformans.
Figure 6Antifungal activity of 3a its metal complexes (plate a) and 3b its metal complexes (plate b) against C. neoformans and C. albicans respectively.
Figure 7Graphical presentation of antimicrobial activity of 4d and 4e.
Minimum inhibitory concentration MIC (μg mL−1) of the newly synthesized 4-hydroxy coumarin analogues and their complexes against different microbial strains against different microbial strains.
| Comps. | |||||
|---|---|---|---|---|---|
| 31.25 | 31.25 | 250 | 31.25 | 31.25 | |
| 31.25 | 31.25 | 31.25 | 31.25 | 31.25 | |
| 31.25 | 31.25 | 31.25 | 31.25 | 31.25 | |
| 31.25 | 31.25 | 31.25 | 31.25 | 250 | |
| >500 | 250 | 31.25 | 31.25 | 31.25 | |
| >500 | 500 | 500 | 500 | 500 | |
| 31.25 | 31.25 | 31.25 | 31.25 | 31.25 | |
| 31.25 | 31.25 | 31.25 | 31.25 | 250 | |
| >500 | 500 | 250 | 31.25 | 31.25 | |
| >500 | >500 | >500 | 500 | >500 |
Escherichia coli.
Klebsiella pneumonia.
Staphylococcus aureus.
Candida albicans.
Cryptococcus neoformans.